Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB

BMC Infectious Diseases

Jie Peng¹  Ye-gui Jiang³  Yong-hong Zhang⁴  Fang-fang Lv²  Shao-hang Cai¹ 

[1] NanFang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China;Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang Province, China;Southwest Hospital, the Third Military Medical University, Chongqing, China;Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China

关键词: HBeAg;    Serum;    Viral load;    Hepatitis B virus;    Cobas TaqMan;    Daan Test;    HBV DNA quantification;   

Others  :  1134651
DOI  :  10.1186/1471-2334-14-85

 received in 2013-06-18, accepted in 2014-02-10,  发布年份 2014

【 摘 要 】

Background

Hepatitis B virus (HBV) DNA levels are crucial for managing chronic hepatitis B (CHB). It was unclear whether Daan real-time polymerase chain reaction test (Daan test) or COBAS TaqMan HBV DNA Test (Cobas TaqMan) was superior in measuring different HBV DNA levels in clinical specimens.

Methods

We enrolled 67 treatment-naïve, HBV surface antigen-positive CHB patients (high baseline viral levels) who received either lamivudine/adefovir or entecavir. Serum samples were tested at baseline and treatment week 24 using the Daan test and Cobas TaqMan.

Results

In the 67-baseline samples, the HBV DNA levels with the Cobas TaqMan (7.90 ± 0.73 log₁₀ IU/mL) were significantly greater than those of the Daan test (7.11 ± 0.44 log₁₀ IU/mL; P < 0.001). Of the 67 24-week samples (low viral levels), the Cobas TaqMan detected 59 (88.1%; 8 undetected); the Daan test detected 33 (49.3%; 34 undetected; P < 0.001). The Cobas TaqMan detected HBV DNA in 26 of 34 samples undetectable by the Daan test (range, 1.4–3.7 log₁₀ IU/mL) or 38% of samples (26/67). The reductions in viral load after 24 weeks of oral antiviral treatment in the 33 samples that were positive for both the Daan test and the Cobas TaqMan test were significantly different (3.59 ± 1.11 log₁₀ IU/mL versus 4.87 ± 1.58 log₁₀ IU/mL, respectively; P = 0.001). Spearman correlation analysis showed positive correlation between results from two tests (r_p = 0.602,P<0.001). The HBV genotypes and the anti-viral treatment did not affect the measurements of the HBV DNA by the Daan assay and the Cobas Taqman assay.

Conclusion

The Cobas Taqman was more sensitive at low viral loads than the Daan test and the change from complete to partial virological response could affect clinical decisions. The Cobas Taqman may be more appropriate for detection of HBV DNA levels.

【 授权许可】

   
2014 Cai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Liaw YF: Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009, 51:403-410.
• [2]Chen P, Yu C, Wu W, Wang J, Ruan B, Ren J, Yang S, Xu K, Yu L, Li L: Serological profile among HBsAg-positive infections in Southeast China: a community-based study. Hepat Mon 2013, 13:e7604.
• [3]Lin YY, Huang JF, Liu SF, Yu ML, Tsai CH, Yang JF, Lin IL, Dai CY, Lin ZY, Chen SC, Chang WY, Chuang WL: Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis 2009, 41:614-618.
• [4]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
• [5]Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-174.
• [6]European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
• [7]Karabay O, Tuna N, Esen S: Comparative efficacy of pegylated interferons alpha-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol 2012, 24:1296-1301.
• [8]Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV: Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013, 20:e37-e46.
• [9]Dogan UB, Golge N, Akin MS: The comparison of the efficacy of pegylated interferon alpha-2a and alpha-2b in chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2013,  .
• [10]Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H: Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther 2010, 15:1171-1178.
• [11]Cai T, Lou G, Yang J, Xu D, Meng Z: Development and evaluation of real-time loop-mediated isothermal amplification for hepatitis B virus DNA quantification: a new tool for HBV management. J Clin Virol 2008, 41:270-276.
• [12]Dai CY, Yu ML, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chuang WL, Chang WY: Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J Clin Pathol 2004, 57:141-145.
• [13]Yuan HJ, Yuen MF, Wong DK, Sum SS, Lai CL: Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. J Clin Microbiol 2004, 42:3513-3517.
• [14]Yim HJ, Byun KS, Chang YJ, Suh YS, Yeon JE, Lee CH, Kwon JA, Yoo W, Kim SO, Hong SP: Levels of hepatitis B virus (HBV) replication during the nonreplicative phase: HBV quantification by real-time PCR in Korea. Dig Dis Sci 2007, 52:2403-2409.
• [15]Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M: Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol 1999, 37:2899-2903.
• [16]Shi M, Zhang Y, Zhu YH, Zhang J, Xu WJ: Comparison of real-time polymerase chain reaction with the COBAS Amplicor test for quantitation of hepatitis B virus DNA in serum samples. World J Gastroenterol 2008, 14:479-483.
• [17]Welzel TM, Miley WJ, Parks TL, Goedert JJ, Whitby D, Ortiz-Conde BA: Real-time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol 2006, 44:3325-3333.
• [18]Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
• [19]Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, Farci P, Lampertico P, Marzano A, Niro G, Pisani G, Prati D, Puoti M, Raimondo G, Santantonio T, Smedile A, Lauria F , Italian Association for the Study of the Liver (AISF): The use of molecular assays in the management of viral hepatitis. Dig Liver Dis 2008, 40:395-404.
• [20]Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42:1414-1419.
• [21]Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005, 42:121-129.
• [22]Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
• [23]Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.